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Current Biology 28, R1-R16, January 8, 2018 of a few model taxa and some welldeveloped theory -we know relatively little. On the latter, the number of mates sampled can have profound effects on the expected genetic correlations between preference and traits that confer attractiveness [2] , and this inter-sexual correlation is in turn a key (theoretical) determinant of the likelihood of Fisherian runaway [3] . However, the numbers of potential mates typically sampled in nature before mating occurs has only been investigated in a handful of taxa, and is often small [2] , and the precise rules (e.g. threshold or best of N) employed in making choices are often unknown [4] . Rosenthal pulls a lot of this together and makes the additional point that experience and learning also infl uence choice, and both they and choice can vary spatially and temporally. One element that would have been helpful for me here would have been Rosenthal's thoughts on comparing preference functions. What should we compare and how? If functions themselves are not statistically signifi cant, should they still be used or not? This latter point has been raised in terms of the inter-sexual genetic correlations between preference and trait, and it was felt that associations should be reported regardless of statistical signifi cance because the magnitudes measured remain our best estimates nonetheless [5] .
It is inevitable that errors creep into a book this broad and deep. Some are editorial and trivial, such as fi gure legend labels not matching fi gures (at least in my copy). Others are slightly more problematic, such as the defi nition of sperm competition being a little unconventional -sperm competition can take place between more than two males. In some areas, I would love to have had morethe section on social environments could have been more expansive for my taste -although the paucity of data here largely determines what could and could not be said. Finally, there are also some bits I am not sure I agree on -how useful is it to think about perimating, for example -but that is the nature of the scientifi c endeavor. We disagree, argue, discuss and the whole venture plows on as debates are clarifi ed and resolved, and prejudices overcome. In any case, I think the book is a triumph. Students of the fi eld need to have it, if only as a reference, because our understanding of mate choice as it now stands is wonderfully captured in this book. For me, Bradbury and Andersson's edited volume [6] remains the most important text for the sexual-selection fi eld, but by focusing on mate choice, and through Herculean effort, Rosenthal has performed a great service to those interested in sexual selection and all my students will be expected to read his excellent text. 
What do you tell students who ask you to refl ect on your career path?
A dictum attributed to Socrates is that "The unexamined life is not worth living." But the obsessively planned and over-analyzed life is not worth living, either. Successful scientists must enjoy hard work, rigor, and hours of thinking about hard problems. However, if I were to select the traits that have been most important in guiding my choices as I moved from academia to government and back again, they are unslakable curiosity, openness to new ideas and experiences, and a willingness to take risks. Given the hypercompetitive world that our students now face -one where misbegotten, pseudo-precise
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Current Biology 28, R1-R16, January 8, 2018 R7 rankings are applied to graduate programs, journals, and scientifi c contributions -it may sound hollow or foolish to encourage curiosity, intellectual breadth, and passion, rather than rational careerism. But I cannot imagine living any other way. Aristotle, another ancient Greek philosopher, wrote that science begins in wonderno mention of impact factors.
That's a rather abstract answer. What led you to become Director of the National Institute of Mental Health early in your career? Directing an NIH institute was not something that I had ever imagined. In truth, I had little understanding of how government science agencies worked and only a vague understanding of what my new position entailed until half a year into my tenure. More than once, I had the thought that the chances of fi nding myself in such a position were similar to the probability of being hit by a meteorite. The major risk factors for that meteorite strike were my clinical training in psychiatry combined with a scientifi c career in molecular neurobiology -a rather uncommon combination in the mid-1990s. Harold Varmus, who had become NIH director, decided to recruit younger, ideally molecularly oriented scientists to replace retiring career administrators as NIH institute directors. He convinced me to leave a fairly blissful academic existence at Massachusetts General Hospital and Harvard University that was composed of my lab, graduate teaching, and participation in an exhilarating University-wide interdisciplinary initiative on Mind, Brain, and Behavior. Indeed, this was a risky leap because I was only 43 when I began, and I had no clear idea of what I would do afterwards. In fact, Harold had intuitively fi gured me out. He made the case that, if I was motivated to exert signifi cant infl uence on the direction of science, the gain of leading NIMH would far outweigh the loss of shrinking my own laboratory efforts. But he reeled me in by letting me know how challenging it would be -tractable of course, but a heavy lift. In the meeting in NIH Building One at which I signed on, Harold described the NIMH scientifi c portfolio as antiquated and incoherent, contributing to a long period of stasis in therapeutics for devastating mental illnesses. I think my memory is accurate that having told me that the institute was a mess, he said that it was my job to fi
How did you decide to get trained in psychiatry in the fi rst place? My path was tortuous indeed -although in retrospect, the story all seems to make sense. After graduating from college, I received a fellowship to the University of Cambridge where I studied History and Philosophy of Science. I had begun planning a doctoral thesis in philosophy focused on the logic of causal inferences in neurobiology made across levels of complexity (molecules, cells, synapses, circuits, cognition, and behavior) -a problem that continues to exercise me to this day, but I will come back to that. However, in 1975, neurobiology was a very young discipline that seemed more exciting to participate in directly than to refl ect on from the outside. I was pessimistic about my chances of being accepted to one of the few neurobiology doctoral programs of the time given my prior studies, but US medical schools professed agnosticism about one's fi eld of undergraduate study so long as one could learn the requisite science. Thus, I applied to and entered Harvard Medical School with the plan of using it as a path to a scientifi c career. I got there in the end, but in the interim discovered -to my horror -that the fi rst two years of medical school in the late 1970s were an intellectual wasteland dedicated to brute memorization of facts delivered by a seemingly random parade of lecturers. Happily, the clinical years that followed were stimulating and motivating because of daily engagement with patients in need of care, endless observation of human disease states, and supervision by many superb clinicians and clinician scientists.
Before heading for the lab fulltime, I thought it would be useful to obtain deeper clinical experience and assumed that I would apply for a residency in neurology. However, I found individuals suffering with schizophrenia, bipolar disorder, severe depression, and other psychiatric conditions riveting to talk with and their plight emotionally moving. Moreover, it was exciting to me that the mechanisms of psychiatric disease remained mysterious and much in need of new scientifi c approaches. Neither the simplistic, reductive explanations of the pharmacologists (such as imbalances of neurotransmitter levels) or the elaborate 'just-so stories' of Harvard's many psychoanalytically trained faculty had much traction on the actual problems posed by severe mental illness. Psychiatric training seemed ideal to me. Patients I could care about, faculty I could fi ght with, and scientifi c mysteries to pursue. Except I made one enormous error. I thought that family and genetic studies, advances in neuroscience, and the newly emerging discipline of molecular biology would soon elucidate pathogenesis and result in improved therapeutics. How wrong I turned out to be, but with that false hope I began fi ve years of postdoctoral fellowship in molecular biology that eventually led me away from the clinic and into the laboratory. 
Has the rate of therapeutic progress really been that slow in psychiatry?
The therapeutic potential of lithium was fi rst recognized in 1949. All currently used antidepressant and antipsychotic drugs are based on prototype compounds serendipitously identifi ed in the 1950s as the result of unexpected effects on humans with depression or schizophrenia. No current antidepressant is more effi cacious than imipramine -the very fi rst identifi ed -although good medicinal chemists have made modern drugs far safer and more tolerable. The most effective antipsychotic drug, clozapine, was fi rst synthesized in the early 1960s, and the basis of its therapeutic advantages is still not understood. There are no pharmacological treatments at all for the most disabling symptoms of schizophrenia, the cognitive impairments and defi cit symptoms, or for the core defi cits in social communication characteristic of autism spectrum disorders (ASDs).
Only now, 35 years after I began psychiatric training, do I believe that we are gaining solid insights into psychiatric disease mechanisms, with the most rapid advances grounded in the genetic analysis of schizophrenia and rare forms of ASDs. As is so often the case in the history of science, it is technology that permits important new observations that lead to new ideas, not the other way around, as many scientists like to believe. Wellpowered genetic studies of complex, heterogeneous human diseases such as schizophrenia became possible because of new genomic technologies and computational tools developed in the context of the Human Genome Project and related endeavors. Similarly, biological studies to follow up on genetic fi ndings are becoming possible -in my viewbecause of the development of stem cell technologies, powerful tools for genome engineering such as CRISPRCas9, and high-throughput methods for single-cell RNA sequencing. Applications of single-cell methods are starting to provide our fi rst classifi cations of the thousands of cell types in human and rodent brains.
It sounds as if the science is beginning to move ahead. What still keeps you up at night? We have made a signifi cant step forward with the success of psychiatric genetics, and I feel very fortunate to be involved as Director of the Stanley Center of the Broad Institute. Yet my nightmare is that we will end up with gene lists rather than mechanistic understandings that will propel therapeutics. For example, we now know of more than 250 signifi cant genomic loci associated with the risk of schizophrenia, and are learning of ever-increasing numbers of both common and rare genetic variants associated with diverse psychiatric disorders. Yet we lack successful experimental paradigms that can turn a growing fl ood of genetic information into biological insights that will make a difference for patients. Indeed, the problem about which I was thinking of writing a doctoral thesis in philosophy so many years ago is still very much with us today: how do we glean causal mechanisms from thousands of DNA sequence variants each of which exerts only a small effect on phenotype? Each individual with schizophrenia has genetic loading for some subset of the many risk-associated alleles segregating in the population, combined with stochastic developmental events and environmental risk factors that increase the risk of disease. These risk factors produce complex changes in the structure and expression of a large number of RNA molecules and proteins in diverse neuronal and glial cell types. In turn, these molecular and cellular effects alter synapses and circuits, and ultimately cognition and behavior. I am fortunate to be surrounded by talented colleagues with access to advanced technology and computational resources. We are dedicated to engaging directly with the genetic complexity and heterogeneity of psychiatric disorders, rather than fl eeing toward feckless reductionism. I am excited by the challenges, heartened by my colleagues, and driven by intense, unmet clinical need. But success will not come easy. 
Stochasticity, individuality and behavior
Kyle Honegger and Benjamin de Bivort
No two individuals are exactly alike. More than a simple platitude, this observation refl ects the fundamentally stochastic nature of biological systems. The term 'stochastic' describes features that cannot be predicted a priori from readily measurable variables. In the dichotomous framework in which biological variation arises from genetic or environmental effects, stochastic effects are classifi ed as environmental because they are not passed on to offspring -any non-heritable cause is, by defi nition, environmental. But non-heritable effects can be subdivided into those which can be predicted from measurable variables, and those that cannot. These latter effects are stochastic.
The existence of unpredictable stochastic effects on biological phenotypes is, oddly enough, guaranteed by deterministic physical laws. The vast numbers of nonlinear inter-molecular interactions involved in cellular function, coupled with thermodynamic instability, make it impossible that the chain of causal events driving organismal development and function will proceed in completely identical ways across organisms. In practice, the outcomes of stochastic events are exceedingly common and feasible to measure at the organismal level, even if their provenance at the molecular level is hidden.
The consequences of stochasticity for an organism are vast and span levels of biological organization from gene expression in single cells through complex patterns of behavior. There are striking stories of monozygotic (colloquially 'identical') twins, separated at birth, who share remarkably specifi c behavioral traits and quirks as adults, despite having been raised in different environments. These individuals share nothing but their genotype and in utero environment. To many, the co-occurrence of such unlikely
